Guest: Ann D. Bass, MD

Guest: Barry A. Singer, MD

Multiple sclerosis is a chronic inflammatory and neurodegenerative disease with a highly variable clinical course.1,2 Most patients who have relapsing-remitting multiple sclerosis (RRMS) will eventually transition to a secondary progressive course (SPMS).3 Patients with SPMS may live with significant impairment in physical and cognitive functions.4 Early identification of disease progression is important.2

Join Dr. Barry Singer from the MS Center for Innovations in Care at the Missouri Baptist Medical Center in St Louis, Missouri as well as Dr. Ann Bass from the Neurology Center of San Antonio in San Antonio, Texas as they share their real-world clinical perspectives on the management of patients with more progressed RMS, including those with aSPMS, and MAYZENT as a treatment option. Together, they will explore the following decision points:

• How to actively identify first signs of RMS progression
• A therapy for progressing RMS, including active SPMS
• What to consider when getting patients started on MAYZENT, a disease-modifying treatment